Description:

Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Keywords:
Versions (2) ▾
  1. 3/4/19
  2. 10/30/19
Copyright Holder:
GlaxoSmithKline
Uploaded on:

October 30, 2019

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556

Cycle 1 Day 21 - Physical Examination; Vital Signs; 12-Lead ECG; Hematology; Clinical Chemistry, Coagulation and Electrolytes; Urinalysis; Urinalysis microscopy results; Serum beta-hCG Pregnancy Test; PK Sampling - Plasma Samples; Study Treatment Compliance (Return); New Adverse Events and Concomitant Treatment

Administrative
Visit Date
Was a physical examination performed?
Physical Examination
Vital Signs
mmHg
mmHg
beats/min
breaths/min
12-Lead ECG
ECG Results
beats/min
msec
msec
msec
msec
ECG Findings
Hematology
Hematology
Clinical Chemistry, Coagulation and Electrolytes
Clinical Chemistry, Coagulation and Electrolytes
Urinalysis dipstick results
Urinalysis microscopy results
Urinalysis microscopy results
Serum beta-hCG Pregnancy Test
PK Sampling - Plasma Samples
Study Treatment Compliance (Return)
New Adverse Events and Concomitant Treatment